Invesco Pharmaceuticals ETF
PJP
81 hedge funds and large institutions have $69.3M invested in Invesco Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
19% more capital invested
Capital invested by funds: $58.4M → $69.3M (+$10.9M)
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
4.02% more ownership
Funds ownership: 18.9% → 22.92% (+4%)
3% more funds holding
Funds holding: 79 → 81 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$8.67M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.47M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.17M |
| 4 |
Morgan Stanley
New York
|
+$833K |
| 5 |
Goldman Sachs
New York
|
+$706K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$239K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$228K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$165K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$158K |
| 5 |
BCM
BTR Capital Management
Oakland,
California
|
-$153K |
PJP Hedge Fund Activity: Q3 2022 in Review
81 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q3 2022, worth a combined $69.3M — up 19% from $58.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PJP positions and 7 closed out — a net gain of 3 holders — while 19 added to existing stakes and 17 trimmed.
The largest buyer was Mirae Asset Global Investments, opening a new position worth an estimated $8.67M. The largest seller was HighTower Advisors, exiting entirely with an estimated $239K sold.
- 81 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q3 2022, up from 79 in Q2 2022.
- Funds reported $69.3M of Invesco Pharmaceuticals ETF stock for Q3 2022, up 19% quarter-over-quarter.
- 10 funds opened new Invesco Pharmaceuticals ETF positions in Q3 2022 and 7 closed out, a net change of +3 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q3 2022 was Mirae Asset Global Investments, an estimated $8.67M added.
- The largest Invesco Pharmaceuticals ETF seller in Q3 2022 was HighTower Advisors, an estimated $239K sold.
Based on aggregated 13F filings for Q3 2022.